Pharmaceuticals and Personal Care Products in the Environment: Regulatory Drivers and Research Needs
Why this work is in the frame
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Bibliographic record
Abstract
Abstract The potential effect of human and veterinary medicines and other personal care products on the environment has become an important topic over the past few years. Whilst an assessment of the potential environmental risks posed by new and existing pharmaceuticals has been required in the United States (U.S.) for a number of decades, in the European Union (EU) and Canada assessments have only been required in the last 5–10 years. In the U.S., guidance has been available since the early 1980s on the assessment of veterinary medicines, whereas only recently has detailed guidance become available on how to perform the risk assessment in other areas. For example, in Canada, new pharmaceuticals (and other substances including novel foods, food additives, human biologics and genetic therapies, medical devices, natural health products, veterinary drugs, cosmetics) have been required to be notified for an environmental assessment under the Canadian Environmental Protection Act (CEPA 1999) since 2001. The European Medicines Evaluation Authority (EMEA) has published guidelines for assessment of veterinary medicines in use in Europe. For veterinary medicines attempts are currently being made by the Veterinary International Co‐operation on Harmonisation (VICH) to harmonise these approaches. Generally, the current assessment approaches are tiered and initially involve a comparison of environmental concentrations with set trigger values. If the trigger values are exceeded then a formal assessment has to be performed requiring data on environmental fate and ecotoxicity. Concerns have been raised over the current approaches used in each of the assessment processes and there are a number of areas that warrant further research. This paper will provide an overview of the regulatory assessment of pharmaceuticals and personal care products (PPCPs) and will expand on many of the topics for research in the future, and the role that QSAR scientists can play in this research will be highlighted.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.001 | 0.005 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it